Meet Me in 5: Building a Long-Term Career at Covance

Our ongoing “Meet me in 5” series covers 5 people, topics or questions to illustrate how Rob Davie CovanceCovance nurtures exceptional people, provides an energized purpose and enables extraordinary potential in its employees’ careers.   

In this article, Rob Davie, vice president & general manager, global clinical development at Covance, shares his thoughts on career ownership, the benefits of our global culture and our competitive advantage.

  1. No two days are ever the same

Rob Davie didn’t originally plan to stay at Covance for 19 years and counting. He first joined Covance after working with a large pharmaceutical company and planned to eventually return to the pharma industry after gaining knowledge and experience with a global contract research organization (CRO). Continue reading

Work That Matters: A Personal Impact

Covance employees working to support clinical trials recognize that they are helping to Socialmedia_LinkedIn1200x627_work-that-mattersmove medicine forward and improve healthcare, but sometimes the impact is much closer to home.

“A client of ours was testing a new formulation of a measles, mumps, rubella and varicella (MMRV) vaccine and needed to ensure the end product was safe in pediatric populations,” explained Joshua. The Phase IV study was running smoothly but needed a Clinical Research Associate (CRA). Joshua was thrilled to take on the study and build on his experience.  Continue reading

Meet Me in 5: Growing Your Career with Covance

Our ongoing “Meet me in 5” series covers 5 people, topics or questions to illustrate how Covance nurtures exceptional people, provides an energized purpose and enables extraordinary potential in its employees’ careers.   

In this edition of Meet Me in 5, our leadership team shares their experiences with nurturing careers at Covance.

Continue reading

Stepping Up the Game: Measles, Mumps, Rubella and Varicella (MMRV) Concomitant Testing Support for Vaccine Evaluation

The introduction of vaccines against Measles, Mumps, Rubella (MMR), and Varicella (the “V” in MMRV vaccines) led to a drop in the incidence of these diseases by 89% (Varicella) and 99% (MMR). These effective vaccines are a core component in most pediatric immunization programs across the world. Hence, every time a new pediatric vaccine is added to the existing immunization schedule, clinical evidence must be provided that the newcomer does not adversely influence the immunogenic response to the MMRV-licensed vaccines. These required non-inferiority studies when vaccines are co-administered (known as concomitant vaccine testing) come with their own challenges.

Continue reading

Hot Topics Discussed in Covance Spring & Summer Webinars

Unlock opportunities for your clinical research programs and deliver results that Covance Spring Webinars Video Nash Diabetic Heart Biomarkersmatter.
We’re excited to be on the cutting edge of drug development solutions. Take a look at our recent webinar topics and leverage our experience.

Going Virtual: Evolving Real World Evidence Study Design for
Speed, Flexibility and Lower Cost

Using a traditional clinical-site recruitment approach is no longer the only option in observational research. With the increased adoption of electronic informed consent methods by the FDA, it is now feasible to conduct real world evidence (RWE) studies using a virtual model that eliminates entirely the need for clinical sites.

Join us to learn how to lower cost and improve the efficacy of current, site-based RWE studies as well as:

  • The implications of electronic informed consent by the FDA
  • What is required to conduct a prospective virtual RWE study
  • How to use electronic data for a retrospective virtual RWE study

September 19, 2017 | 11 a.m. EDT | Register Now

 

Continue reading

Precision Medicine in Immuno-Oncology

The NIH defines precision medicine as “an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person1.” In cancer patients, we can rephrase the definition to “through detailed understanding of a cancer’s biology, providing the right drug, for the right patient, at the right time.” Covance CRO Labs Blog

In order to identify the correct drug, biomarkers are used to identify patients that can be treated with the appropriate therapy for their cancer. The FDA defines biomarkers as “a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions2.” Great strides have been made in the discovery and validation of biomarkers in drug development. Continue reading

Fierce Innovation Awards Recognize Xcellerate® Trial Design As Best Data Analytics/Business Intelligence Technology

Covance is proud to announce that Xcellerate® Trial Design has been selected as the Fierce Innovation Awards Recognize Xcellerate® Trial Design winner of the Fierce Innovation Awards: Life Sciences Edition in the Data Analytics/Business Intelligence category. The Fierce Innovation Awards: Life Sciences Edition recognizes outstanding innovations that are driving improvements and transforming the life sciences industry. Xcellerate Trial Design was recognized for its innovative approach to improving site selection, forecasting resource demand and optimizing of clinical trial design. Continue reading

Computerworld Names Dimitris Agrafiotis of Covance a 2017 Premier 100 Technology Leader

Agrafiotis’ Leadership in Bringing Xcellerate® Informatics to Market Demonstrates How Software Can Improve Health and Improve Lives

IDG’s Computerworld recently recognized Dimitris Agrafiotis, PhD, chief data officer and Computerworld Dimitris Agrafiotis head of technology products for Covance Drug Development, as a 2017 Premier 100 Technology Leaders honoree. This year’s Premier 100 spotlights 100 leaders from both the technology and business sides of companies for their exceptional technology leadership and innovative approaches to business challenges. Covance is the drug development business of LabCorp.

“The Premier 100 awards program highlights the exceptional work of an elite group of IT executives who are leading their organizations through times of unprecedented change. They are using technology to drive high-stakes business projects and create dynamic growth in their organizations,” said Scot Finnie, editor in chief of Computerworld.

“These 100 men and women are not only strategic business thinkers, but also team leaders who recognize the importance of recruiting and retaining the brightest talent to enable digital transformation and harness the opportunities of cloud, big data, mobile and social. We’re pleased to recognize their leadership and honor their achievements.” Continue reading

Risk-Based Monitoring – Driving the Evolution of the Clinical Research Associate Role

Over the last 10 years, clinical trials have changed substantially in response to increasing globalization and study complexity, along with new technological capabilities and industry guidelines[1],7. With these noticeable transformations, sponsors are increasingly revisiting their monitoring methods to uncover new efficiencies and develop more robust risk management processes that can enhance ongoing patient safety and data quality.

At the forefront of this movement is risk-based monitoring (RBM) – a broad term for a variety of clinical monitoring methods that combine people, process and technology, enabling project teams and Clinical Research Associates (CRAs) to focus on the most important risks in clinical trials.

Clinical Research Associate Covance CRA Careers

Continue reading

An Insider’s View on Working for Covance

Since starting my drug development journey as quality assurance manager in a laboratory Working for Covance that would later become part of Covance to now serving as the CEO, I’ve witnessed our industry’s notable shift to support more nimble drug development. From improved trial design to companion diagnostics and more predictive insights fueled by advanced informatics, it’s exciting to see bold ideas enable smarter decisions and speed the introduction of groundbreaking therapies.

Progress is evident in many areas—starting at early phases through market access—but one factor remains constant throughout the years: our hard-working employees continue to advance innovation. They are the reason we can deliver unique perspectives that shape new solutions and carry out the vision of a healthier future. Continue reading